Characterization of the Depletion of 2-C-Methyl-D-Erythritol-2,4-Cyclo-diphosphate Synthase in Escherichia coli and Bacillus subtilis

Tracey L. Campbell and Eric D. Brown*
Antimicrobial Research Centre, Department of Biochemistry, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
Received 8 May 2002/Accepted 16 July 2002

The ispf gene product in Escherichia coli has been shown to catalyze the formation of 2-C-methyl-D-erythritol 2,4-cyclo-diphosphate (MEC) in the deoxyxylulose (DOXP) pathway for isoprenoid biosynthesis. In this work, the E. coli gene ispf and its Bacillus subtilis orthologue, yacN, were deleted and conditionally complemented by expression of these genes from distant loci in the respective organisms. In E. coli, complementation was achieved through integration of ispf at the araBAD locus with control from the arabinose-inducible araBAD promoter, while in B. subtilis, yacN was placed at amyE under control of the xylose-inducible xylA promoter. In both cases, growth was severely retarded in the absence of inducer, consistent with these genes being essential for survival. E. coli cells depleted of MEC synthase revealed a filamentous phenotype. This was in contrast to the depletion of MEC synthase in B. subtilis, which resulted in a loss of rod shape, irregular septation, multi-compartmentalized cells, and thickened cell walls. To probe the nature of the predominant deficiency of MEC synthase-depleted cells, we investigated the sensitivity of these conditionally complemented mutants, grown with various concentrations of inducer, to a wide variety antibiotics. Synthetic lethal behavior in MEC synthase-depleted cells was prevalent for cell wall-active antibiotics.

Isoprenoids comprise a diverse group of compounds with over 30,000 members that are unique in both their chemistry and structure (34). All isoprenoids are made from the same basic five-carbon isoprene unit, isopentenyl pyrophosphate (IPP) and its isomer, dimethylallyl pyrophosphate (DMAPP). Initial work on the isoprenoid biosynthetic pathway was done predominantly with yeast and animals, and led to the discovery of the mevalonate pathway, which until recently was believed to be the only route for isoprenoid biosynthesis (14, 23). In 1993, Rohmer et al. showed that 13C-labeled precursors were incorporated into isoprenoids in some eubacteria in a labeling pattern that was inconsistent with the mevalonate pathway (32). Shortly after, a new pathway stemming from 1-deoxy-D-xylulose 5-phosphate (DOXP) was discovered, and it is now known as the DOXP pathway or the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway (33).

In the DOXP pathway, DOXP is made from pyruvate and glyceraldehyde-3-phosphate, a reaction catalyzed by the enzyme DOXP synthase (Dxs) (22, 39). In the first committed step of this pathway, MEP synthase catalyzes the isomerization and reduction of DOXP to form MEP (40). MEP is subsequently converted into 4-diphosphocytidyl-2-C-methylythritol (CDP-ME) by a cytidyltransferase known as IspD (formerly YgbP) (31). The next step is an ATP-dependent phosphorylation of CDP-ME at the C-2 hydroxy group to form 4-diphosphocytidyl-2-C-methylerythritol-2-phosphate (26). This product is converted by a unique cyclization reaction, catalyzed by IspF (formerly YgbB), into 2-C-methyl-D-erythritol 2,4-cyclo-diphosphate (MEC) (19). These first steps of the DOXP pathway have been discussed in more detail in some recent reviews (23, 30). The last two steps in this pathway leading to the formation of IPP and DMAPP have only just been identified. Following the formation of the cyclic diphosphate, IspG (formerly designated GcpE) catalyzes a two-electron reduction forming 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (18). In the final step of the DOXP pathway, branching occurs and IPP and DMAPP are formed from 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate by separate reactions catalyzed by the IspH protein (formerly designated LtyB) (29).

The distribution of the DOXP pathway has revealed that the majority of eubacteria use this pathway, while archaea, fungi, and animals appear to use only the mevalonate pathway (8, 23, 30). Higher plants, such as Arabidopsis thaliana, have all of the genes for both pathways, with the mevalonate pathway being used exclusively in the cytoplasm and the DOXP pathway being used exclusively in the plastids (2). The DOXP pathway is present in many pathogenic bacteria, plants, and the malaria parasite, making this pathway an intriguing target for the development of antibacterial compounds, herbicides, and antimalarial drugs (28, 30).

Two independent groups have noted the indispensability of the gene ispf in Escherichia coli (7, 15). Campos et al. replaced the chromosomal copies of ispD, ispE, and ispf with chloramphenicol (CM) resistance markers and were able to complement these mutations with a synthetic operon for the mevalonate-dependent pathway coding for yeast 5-diphosphomevalonate decarboxylase, human 5-phosphomevalonate kinase, yeast mevalonate kinase, and E. coli isopentenyl diphosphate isomerase (7). Gene ispf has likewise been listed as an essential gene in a large-scale gene knockout study reported by...
Freiberg and coworkers (15). To date, however, the physiological consequences of MEC synthase depletion in *E. coli* have not been examined. Moreover, the dispensability of the DOXP pathway for isoprenoid synthesis in the model gram-positive rod *Bacillus subtilis* has not been addressed.

Known functions of isoprenoids include the modification of tRNA (5), dolichol production, and the formation of the respiratory quinones (36). Indispensable roles for the latter two have not been examined. Moreover, the dispensability of the DOXP pathway for isoprenoid synthesis in the model gram-positive rod *Bacillus subtilis* has not been addressed.

**MATERIALS AND METHODS**

**General methods.** Tables 1 and 2 list the strains, plasmids, and primers used. *E. coli* and *B. subtilis* strains were grown in rich Luria-Bertani (LB) medium. The following concentrations of antibiotics were used for *E. coli*: kanamycin (KAN), 25 μg/ml; CM, 20 μg/ml; and ampicillin (AMP), 50 μg/ml. The following concentrations of antibiotics were used for *B. subtilis*: CM, 5 μg/ml; and spectinomycin (SPEC), 150 μg/ml. When required, sucrose was used at a final concentration of 5% (wt/vol), and unless otherwise indicated, arabinose was used at 0.2% (wt/vol) and xylose was used at 2% (wt/vol). HotStarTaq PCR reagents, gel extraction kits, and plasmid Mini-Prep kits were from Qiagen (Mississauga, Ontario, Canada). Cloning was performed in the *E. coli* cloning strain Novablue (Novagen, Madison, Wis.) according to established methods (35). Preparation and transformation of *E. coli* electrocompetent cells were done according to the electroporator manufacturer’s instructions (Bio-Rad, Inc., Hercules, Calif.), while *B. subtilis* competent cells and transformations were done according to established methods (10). Transformations into competent strains were done with 100 ng to 1 μg of DNA. Restriction enzymes and Vent polymerase were obtained from New England Biolabs (Beverly, Mass.), with the exception of *SrfI*, which was purchased from Stratagene (La Jolla, Calif.).

**Construction of araBAD deletion plasmid.** A crossover PCR strategy adapted from reference 24 was used to amplify 500 bp upstream and 500 bp downstream of *araBAD* from *E. coli* MG1655 chromosomal DNA with primers BAD-a, BAD-b, BAD-c, and transformation of *E. coli* strains was done according to established methods (35). Preparative cloning strain Novablue (Novagen, Madison, Wis.) according to established methods (35). Preparation and transformation of *E. coli* electrocompetent cells were done according to the electroporator manufacturer’s instructions (Bio-Rad, Inc., Hercules, Calif.), while *B. subtilis* competent cells and transformations were done according to established methods (10). Transformations into competent strains were done with 100 ng to 1 μg of DNA. Restriction enzymes and Vent polymerase were obtained from New England Biolabs (Beverly, Mass.), with the exception of *SrfI*, which was purchased from Stratagene (La Jolla, Calif.).

**TABLE 1. E. coli strains, plasmids, and primers used in this study**

| Strain, plasmid, or oligonucleotide | Descriptiona | Reference, source, or site |
|-------------------------------------|--------------|-----------------------------|
| Strains                             |              |                             |
| Novablue                            | endA1 hsdS17 (rK2^- :mK2^- ) supE44 thy-1 recA496 relA1 lac [F' proA1- B lacI22(71)M15::Tn10] | Novagen |
| EB68                                | MG1655 (F^- λ^- ) | George Church, Harvard Medical School (24) |
| EB356                               | MG1655 (F^- λ^- ) araBAD::ispF (optimal RBS) kan | This work |
| EB370                               | MG1655 (F^- λ^- ) araBAD::ispF (optimal RBS) kan ΔispF | This work |
| Plasmids                            |              |                             |
| pKO3                                | *E. coli* gene replacement plasmid described by Link and coworkers | 24 |
| pKO3-ispFflank                      | pKO3 with *ispF* flanks from EB68 | This work |
| pKD46                               | Red recombinase expression plasmid for transformation of linear DNA in *E. coli* | 11 |
| pBluescript SKH1+                   | Cloning vector | Stratagene (La Jolla, Calif.) |
| pBS-araBADflank                     | pBluescript with *araBAD* flanks from EB68 | This work |
| pBS-araBADflankkan                  | pBluescript with Kan' cassette inserted between *araBAD* flanking sequence | This work |
| pBS-araBADflankkanisksFkan          | pBluescript with *ispF* (optimal RBS) and Kan' cassette inserted between *araBAD* flanking sequence | This work |

**Oligonucleotides**

| BAD-a | 5'-AAAGAAAAAGCCGCGCGAGATTTGAGATTGAGAATATA-3' |
| BAD-b | 5'-CAACGATACCTCATCGCCGCGGACGACGCGGATATGAGA-3' |
| BAD-c | 5'-CGACGATATGTCGGCTTCAGCGGCTTACGCTGACCC-3' |
| BAD-d | 5'-CGACGATATGTCGGCTTCAGCGGCTTACGCTGACCC-3' |
| BAD-e | 5'-ATCGAGGATTTTCCAGATGCTTAC-3' |
| kan-F | 5'-TGTGTTTAAACGATTTGAGATTGAGAATATA-3' |
| kan-R | 5'-TTAATCAATTGTGATTGAAACGCGCGGATATGAGA-3' |

a. Underlined sequences indicate restriction enzyme sites.

b. Boldface sequence indicates complementarity between BAD-a and BAD-c.

c. Boldface sequence indicates optimal ribosome binding site (RBS).

d. Boldface sequence indicates complementarity between *ispF*-b and *ispF*-c.
TABLE 2. *B. subtilis* strains, plasmids, and primers used in this study

| Strain, plasmid or oligonucleotide | Descriptiona | Reference, source, or site |
|------------------------------------|--------------|---------------------------|
| Strains                            |              |                           |
| EB6                                | hisA1 argC4 metC3 | L5087 (6) This work       |
| EB315                              | hisA1 argC4 metC3 amyE::xyR P_{SaIk} yacN cat86 | This work |
| EB23                               | hisA1 argC4 metC3 amyE::xyR P_{SaIk} yacN cat86 yacN::spec | This work |
| Plasmids                           |              |                           |
| pBSyacNflank                       | pBlueScript with yacN flanks from EB6 | This work |
| pBSyacNflankspec                   | pBlueScript with Spec' cassette inserted between yacN flanking sequence | This work |
| pSWEET-yacN                        | pSWEET with wild-type yacN from EB6 | This work |
| pUS19                               | pUC19 derivative containing Spec' cassette | P. Levin |
| Oligonucleotides                   |              |                           |
| yacN-F                             | 5'-GGGATTTAACTGGGAGAACGAGGCAGGAAACAAAATGTTTGAATTTGCAAG | PucI |
| yacN-R                             | 5'-GGGATTTAACTGGGAGAACGAGGCAGGAAACAAAATGTTTGAATTTGCAAG | NheI |
| yacN-a                             | 5'-GGGATTTAACTGGGAGAACGAGGCAGGAAACAAAATGTTTGAATTTGCAAG | BamHI |
| yacN-ba                           | 5'-CCGCGATGCTGCCGGCGCATAATTATAACCTAATAAGCTGTTTTAATTCTCCTTGTACGCCCTG | SrfI |
| yacN-c                             | 5'-GGTATATAAGTGGGGCCGCCAGGTATATGTCGTGTTTGTTGATCGCGGGTCTATTTGTGTGGG | SrfI |
| yacN-d                             | 5'-GGGATTTAACTGGGAGAACGAGGCAGGAAACAAAATGTTTGAATTTGCAAG | BamHI |
| yacN-e                             | 5'-GGGATTTAACTGGGAGAACGAGGCAGGAAACAAAATGTTTGAATTTGCAAG | BamHI |
| spec-F                             | 5'-GATTGATTTCTGCCTGCACTGACATGCGATGGAGCTGG | SrfI |
| spec-R                             | 5'-TATATGTTTTTTTATCATGTTTTAATCTATGTTTATAGAG | SrfI |

a Underlined sequences indicate restriction enzyme sites.

b Boldface sequence indicates sequence upstream of yacN including the ribosome binding site.

c Boldface sequence indicates complementarity between yacN-a and yacN-c.

d Boldface and italic sequence indicates a conservative histidine mutation in yacN to delete the yacN start codon.

not the terminator, with the introduction of an upstream *PmeI* restriction site. This PCR product was cloned into pBS-araBAD-flank at the *SfiI* site, and a plasmid with the *kan* cassette in the forward orientation with respect to the *araBAD* promoter was chosen and named “pBS-araBAD-flankkan.” Amplification of *ispF* from MG1655 chromosomal DNA was done with primers *ispF*-F (which places a consensus ribosome binding site upstream of *ispF*) and *ispF*-R with Vent polymerase. This PCR product was cloned into the *NdeI* site of pBS-araBAD-flankkan, and a plasmid with *ispF* in the forward orientation with respect to the *araBAD* promoter was selected and named “pBS-araBAD-flankkanispF."  

**Construction of *ispF* deletion plasmid.** As described above, a crossover PCR strategy was used to amplify sequence 500 bp upstream and 500 bp downstream of *ispF* from MG1655 chromosomal DNA with primers *ispF*-a, *ispF*-b, *ispF*-c, and *ispF*-d. The final PCR product was cloned into pKO3 (24) at the *NotI* and *SalI* restriction sites. This new plasmid was named “pKO3-ispFflank.”  

**Precise deletion of *E. coli* *ispF*.** The deletion of *ispF* was carried out as described by Datsenko et al. and Link et al. (11, 24) with slight modifications. LinearizDNA was PCR amplified from pBS-araBAD-flankkanispF with primers *BadA*-d and *BadD*-d, resulting in an approximately 2,500-bp product. MG1655-pKD46 was transformed with 100 ng of this product and plated on Kan select.  

**Construction of pSWEET-yacN plasmid.** Plasmid pSWEET-ysgB (4) was digested with *PacI* and *NheI* to remove *ysgB*. *B. subtilis* 168 chromosomal DNA was used as a template for the amplification of *yacN* with primers *yacN-a* and *yacN-R*. The upstream primer was designed to place *yacN* under the control of the ribosome binding site preceding the open reading frame of *yacN*. (The gene *yacM* is upstream of and overlaps *yacN* by 7 bp.) The PCR product was cloned into pSWEET-ysgB at the *PacI* and *NheI* restriction sites, and the resulting plasmid was named “pSWEET-yacN.”  

**Construction of yacN deletion plasmid.** A crossover PCR strategy, as described above, was used to amplify sequence from *B. subtilis* 168 chromosomal DNA 500 bp upstream of *yacN* and 350 bp downstream of it. This was done with primers *yacN-a*, *yacN-b*, *yacN-c*, and *yacN-d*. Primer *yacN-b* contains a silent mutation in His231 of *yacM* (CAT to CAG) to disrupt the start codon of *yacN* without altering the product of *yacM*. The final PCR product was purified and cloned into pBlueScript at the *EcoRV* site, and the resulting plasmid was named “pBS-yacNflank." A SPEC cassette was amplified with Vent polymerase from pUS19, amplifying the transcriptional promoter, but not the terminator, and was cloned into pBS-yacNflank at the *SfiI* site. Restriction mapping facilitated the choice of a clone in which the orientation of the SPEC cassette conserved the transcriptional context of *yacN*, and the resulting plasmid was named “pBS-yacNflankpec."  

**Precise deletion of *B. subtilis* *yacN*.** Plasmid pSWEET-yacN was digested with *PstI*, gel purified, and used to transform *B. subtilis* 168 cells. Transformants were screened for CM resistance and then restreaked on starch plates to test for disruption of *amyE* (9). A strain that did not produce halos was selected and named “EB315.” Plasmid pBS-yacNflankpec was digested with *PstI* and gel purified. The purified fragment was transformed into strain EB315, and the resulting strain was named “EB323.” Genomic DNA was prepared from strain EB323, and PCR was performed with primers *yacN-a* and *yacN-d* to verify deletion of *yacN."  

**B. subtilis growth curve.** EB315 and EB323 were grown overnight on LB/CM and LB/CM/SPEC/xylose plates, respectively, at 30°C. The following day, the cells were resuspended in 2 ml of sterile saline, and both cultures were diluted to an optical density at 600 nm (OD600) of 0.5. One milliliter of EB315 was inoculated into 100 ml of LB/CM/SPEC/xylose. One milliliter of EB323 was used to inoculate 100 ml of LB/CM/SPEC/xylose (2, 0.2, 0.063, 0.02, and 0%). The samples were incubated at 30°C with shaking at 250 rpm for 1,020 min. Every hour, the OD600 for a 0.5-ml sample was read.

**Light microscopy.** Samples to be examined were prepared by growing the cells on plates with the appropriate selection overnight and resuspending the cells in 2 ml of sterile saline the following day. The cells were pelleted at 2,500 × g, and the pellet was resuspended in 1 ml of sterile saline plus 30% (vol/vol) glycerol. Phase-contrast microscopy was used to view live cells with an Olympus BX51 microscope with a ×100 oil immersion lens. Images were captured with a Cool- SNAP-Pro 12-bit monochrome camera with Image-Pro Express version 4.0 software.

**Transmission electron microscopy.** For transmission electron microscopy, cells were grown as described above for light microscopy and resuspended in 2 ml of sterile saline the following day. The cells were pelleted at 2,500 × g, the saline was removed, and 2% (vol/vol) glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) was added. Samples were refrigerated at 4°C for 24 h to allow fixing to occur. Following this time period, the samples were postfixed with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer (pH 7.4), and dehydration was performed with a graded ethanol series. The samples were then treated with...
propylene oxide and embedded in Spurr's resin. Sections (70 nm) were stained for 5 min with uranyl acetate and for 2 min with lead citrate. Samples were visualized with and photographed with a JEOL 1200EX transmission electron microscope (JEOL, Ltd., Tokyo, Japan) operating at 80 kV.

**Scanning electron microscopy.** For scanning electron microscopy, cells were grown as described above for light microscopy and resuspended in 2 ml of sterile saline the following day. The cells were pelleted at 2,300 × g, the saline was removed, and the cells were resuspended in 2% (vol/vol) glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Samples were refrigerated at 4°C for 24 h to allow fixing to occur. Following this time period, the samples were postfixed with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer (pH 7.4), and dehydration was performed with a graded ethanol series. Samples were visualized and photographed with a PHILIPS 510B scanning electron microscope.

**MICs of antibacterial agents for B. subtilis.** Strains EB6, EB315, and EB323 were grown overnight on LB, LB/KAN, and LB/KAN/xylose plates, respectively. Cells were resuspended from the plates in saline and added to LB with the appropriate antibiotics at a final concentration of 25,000 CFU per 100 μl. Medium (100 μl) containing antibiotics, xylose, and cells was added to each well of a 96-well microtiter plate. Strain EB6 was tested in the absence of xylose, strain EB315 was tested in both the presence (2%) and absence of xylose, and strain EB323 was tested over a range of xylose concentrations of 2, 0.2, 0.063, 0.02, and 0%. The MICs of various antibacterial agents specific for gram-positive organisms were determined for each of the three strains at all levels of xylose by adding the drugs to the wells of the microtiter plate in twofold dilutions and incubating the plates at 30°C with shaking at 200 rpm. After 24 h, the OD for each well of the plate was determined with a Spectra-max Plus instrument (Molecular Devices, Sunnyvale, Calif.). The MIC was assigned as the lowest concentration of drug that inhibited growth of a particular strain.

**MICs of antibacterial agents for E. coli.** Strains EB68, EB356, and EB370 were grown overnight on LB, LB/KAN, and LB/KAN/xylose plates, respectively. One colony from each plate was used to inoculate an overnight liquid culture for each strain, with EB370 grown in the absence of arabinose. This step is required for the overnight cultures), and the cultures were grown until the cells reached an OD600 of 0.3 to 0.5. The cells were added to fresh media at a final concentration of 25,000 CFU per 100 ml. Medium (100 ml) containing antibiotics, xylose, and cells was added to each well of a 96-well microtiter plate. Strain EB68 was tested in the absence of xylose, strain EB356 was tested in both the presence (2%) and absence of xylose, and strain EB370 grown over a range of arabinose concentrations of 0.2, 0.02, 0.0063, 0.002, and 0%. The MICs of various antibacterial agents specific for gram-negative organisms were determined for each of the three strains at all levels of xylose by adding the drugs to the wells of the microtiter plate in twofold dilutions and incubating the plates at 30°C with shaking at 200 rpm. After 24 h, the OD for each well of the plate was determined with a Spectra-max Plus instrument (Molecular Devices, Sunnyvale, Calif.). The MIC was assigned as the lowest concentration of drug that inhibited growth of a particular strain.

**RESULTS**

**Conditional complementation of E. coli ispF and B. subtilis yacN deletion.** E. coli strains EB356 and EB370 were grown at 37°C on agar plates containing LB/KAN with and without arabinose. A similar experiment was done at 30°C for B. subtilis strains EB315 and EB323 with plates containing LB/CM and either 2% or no xylose. The results from these plate experiments are shown in Fig. 1. The E. coli ispF deletion strain (EB370), as seen in Fig. 1A, was able to grow well in the presence of arabinose, showing a wild-type colony morphology, but upon its removal, there was a distinct decrease in growth and a loss of the ability to form single colonies. The same results were seen for the B. subtilis yacN deletion strain, EB323 (Fig. 1B), which had an even more pronounced decrease in cell growth in the absence of complementation. In both cases, the strains with an additional copy of either ispF or yacN, at the arabABD or amyE loci, respectively, were able to grow equally well in both the presence and absence of inducer. These results show that the poor growth of E. coli strain EB370 and B. subtilis strain EB323 in the absence of inducer is a consequence of the depletion of MEC synthase. The small amount of growth observed with E. coli strain EB370 in the absence of arabinose can be attributed to incomplete depletion of MEC synthase, which requires further passage in the absence of arabinose. These experiments represent the first time that yacN has been conditionally complemented and illustrate the tight control of MEC synthase expression that has been achieved in this work.

**IspF- and YacN-depleted cells show altered cell morphology from the wild type and from another.** The growth of both deletion strains was minimal in the absence of inducer, but with a heavy inoculum, enough cells could be obtained for microscopic examination. Depletion of the 2-C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (MEC synthase) in E. coli led to a filamentous phenotype (Fig. 2). To examine the ultrastructure of these long filamentous cells, transmission electron microscopy was used (Fig. 2A). Most striking was the finding that there do not appear to be any visible septa within the filaments, although there may be some points of constriction visible near the ends of the cells. It is difficult to determine if the filaments are plurinucleoid, because distinct DNA-containing regions are indiscernible. Further examination by light microscopy revealed cells up to 36 μm in length, 18 times longer than wild-type cells (Fig. 2B). To examine the surface morphology of the cells in detail, scanning electron microscopy was used (Fig. 2C). These micrographs indicate that despite the filamentous shape, IspF-depleted cells have a normal surface appearance comparable to the exterior of wild-type E. coli cells. It is noteworthy that no visible constrictions were observed, and the filaments appeared to be one long continuous cell. In all cases, the appearance of E. coli strain EB370 grown in the presence of arabinose was identical to that of E. coli strain EB356 (data not shown). Overall, the most striking phenotypic characteristic associated with IspF depletion in E. coli was the presence of long filamentous cells that appear to be lacking septa.

Similar examination of B. subtilis YacN-depleted cells compared with strain EB315 is illustrated in Fig. 3. Light microscopy (Fig. 3A) shows that depletion of MEC synthase resulted in an altered cell shape from the normal rod-shaped cells of B. subtilis. There was bulging around the central region of the cell, and in some cases, there were clumps of almost spherical cells (data not shown). Ultrastructural examination of these cells is shown in Fig. 3B. The MEC synthase-depleted strain (EB323) was a multicompartmentalized cell of irregular shape. The cell walls were of various thicknesses in different regions of the cell, and the septa were not confined to the medial region of the cell, but were located irregularly throughout the entire bacterium. Some of the compartments also appeared to lack a well-defined nucleoid region and likely lack chromatin bodies. Surface examination of MEC synthase-depleted cells is shown in Fig. 3C. Again, what is obvious is the altered cell morphology from the ordinary rod shape, and in addition, there was the appearance of grooves along the surface with a large furrow at the central portion of the cell. In all cases, cells of strain EB315 (right panels) were similar in appearance to wild-type B. subtilis cells, and fully complemented strain EB323 resembled EB315 (data not shown). These micrographs show that depletion of MEC synthase in E. coli and B. subtilis causes an altered cellular morphology from that of cells with normal levels of this protein. Additionally, the phenotype observed in E. coli was
markedly different from that seen in *B. subtilis*, despite the depletion of orthologous proteins.

YacN-depleted cells show an altered growth rate and morphology depending on the level of inducer. Figure 4 highlights the impact of depletion of MEC synthase in the *B. subtilis* yacN mutant (EB323), where the growth in liquid media was monitored at various concentrations of inducer relative to that of the control strain (EB315). At 2% xylose, *B. subtilis* strain EB323 had a slightly increased lag period compared with the control (EB315), but was able to grow at the same rate during the exponential phase and reached a similar final cell density, as determined by the $A_{600}$. As the level of inducer was decreased, an increase in the lag phase was observed along with a decrease in the growth rate during the exponential phase. In the absence of any inducer, there was almost no discernible growth over the time course of the experiment. These results indicate that the ability of *B. subtilis* strain EB323 to grow is related to the expression of MEC synthase in the cell.

Transmission electron micrographs were taken of *B. subtilis* strain EB323 at the inducer levels used in Fig. 4. At the 2 and 0.2% levels of inducer, the cells appeared as normal rod-shaped *B. subtilis*. At 0.063% xylose, the cells were still normal in appearance, but cell lysis was beginning to occur. In the absence of inducer, cells were altered in their morphology and
showed a loss of rod shape and multiple septa with irregular wall thickness. Interestingly, as the level of inducer was decreased, there was a corresponding decrease in growth rate, but the cells remained normal in appearance until full depletion was achieved.

In this work, we have confined our microscopic analysis of the incremental depletion of MEC synthase to *B. subtilis*. In *E. coli*, using the araBAD promoter, the autocatalytic nature of arabinose transport is understood to lead to a mixed population of fully induced and fully repressed cells at subsaturating concentrations of inducer (37).

**IspF- and YacN-depleted strains are sensitive to cell wall-active antibacterial agents.** We have exploited the principle of synthetic lethal interactions in an attempt to better understand the mechanism of MEC synthase depletion. The susceptibility of *E. coli* and *B. subtilis* strains depleted of MEC synthase to a diverse collection of antibacterial agents was tested. These agents targeted cell wall, protein synthesis, nucleic acid synthesis, metabolic pathways, and the cell membrane (Table 3). For each of these targets, the antibiotics selected were of different chemical classes, where possible, in an effort to establish a consensus by using multiple and diverse probes of each. Table 3 shows that both *E. coli* and *B. subtilis* complemented mutants showed an increased sensitivity (represented by a lower MIC) to cell wall inhibitors as the level of inducer was decreased. We show a subset of the graphical data for these experiments in Fig. 5. A similar sensitization was noted with the antibiotic fosmidomycin. Fosmidomycin is a known inhibitor of the DOXP pathway, inhibiting the enzyme MEP synthase, which represents the first committed step in the pathway (20, 21). In contrast, the potency of inhibitors of protein synthesis, nucleic acid synthesis, one-carbon metabolism (trimethoprim), and membrane integrity was unaffected by the level of inducer present. In a few of these cases, however, a slight decrease in MIC was seen at the lowest level of inducer tested. This is presumably due to a more trivial relationship between antibiotic potency and general cell fitness due to extreme depletion of MEC synthase. In aggregate, these experiments demonstrated a synthetic lethal interaction between cell wall-active agents and the DOXP pathway inhibitor fosmidomycin with the *ispF* and *yacN* mutants.
DISCUSSION

In bacteria, isoprenoids are thought to be required for three distinct purposes: the modification of tRNA, believed to serve as a regulatory device (5), the formation of dolichols, and the production of the respiratory quinones (36). It follows that, if nonredundant, the DOXP pathway for isoprenoid biosynthesis ought to be indispensable for the growth of *E. coli* and *B. subtilis*. Furthermore, it is possible that isoprenoids also have unrecognized roles in bacterial physiology. We have endeavored in this work to rigorously address the dispensability question for MEC synthase of the DOXP pathway for isoprenoid biosynthesis. In addition, we have probed the mechanism and dominant physiological effects of a lesion in the DOXP pathway with mutants with conditional mutations in the *ispF* and *yacN* genes encoding MEC synthase in *E. coli* and *B. subtilis*.

We have shown that MEC synthase is essential for the growth of *E. coli* and *B. subtilis*. Depletion of these products resulted in a decreased growth rate and altered cell morphology; however, most striking was the finding that MEC synthase-depleted *E. coli* and *B. subtilis* have very different cell shapes and ultrastructures. In *E. coli*, depletion of IspF resulted in long filamentous cells, which appear to lack septa. Although peptidoglycan biosynthesis is required for both elongation and septum formation in *E. coli*, these processes represent two distinct morphogenic pathways, and so it is possible for one to be functional in the absence of the other (25). Long filamentous *E. coli* cells typically result from an inability to form septa (13). Multinucleate, filamentous cells with blunt constrictions are seen with FtsI (PBP3) mutants (12, 27), while FtsZ mutants give smooth filaments with no visible constric-
tions (27). FtsI has dideoxy-transpeptidase activity and is required for septal murein synthesis (13). FtsZ acts before FtsI and is required to form a cytokinetic ring at the division site followed by the assembly of murein biosynthetic and hydrolytic enzymes (27). The *E. coli* MEC synthase deletion strain created in this work was filamentous, with possible points of constriction. Synthesis of peptidoglycan requires dolichol phosphates in the cell membrane as carriers for assembly of disaccharide pentapeptide (36). Interestingly, it is believed that the amount of dolichol monophosphates available to the bacterium is the rate-limiting step in peptidoglycan biosynthesis (16). It follows, therefore, that depletion of MEC synthase in

---

**FIG. 5.** Sensitivity of *E. coli* and *B. subtilis* MEC synthase-depleted cells to various antibacterial agents. (A) Change in MIC for the *B. subtilis* MEC synthase deletion strain (EB323) with various concentrations of inducer to representative antibacterial agents. Fold sensitization in MIC is calculated with respect to the fully complemented deletion strain (2% xylose). From left to right, the amounts of xylose are as follows: 2, 0.2, 0.063, and 0.02%. Cells were grown in a volume of 100 µl in a 96-well microtiter plate for 24 h, and then the *A*<sub>600</sub> was read. (B) Change in sensitivity of *E. coli* MEC synthase deletion strain (EB370) to antibacterial agents with various concentrations of inducer. Fold sensitization in MIC is calculated with respect to the fully complemented deletion strain (0.2% arabinose). From left to right, the amounts of arabinose are as follows: 0.2, 0.02, 0.0063, and 0.002%. Cells were grown in a volume of 150 µl in a 96-well microtiter plate for 16 h, and then the *A*<sub>600</sub> was read. In all cases, the MIC was determined as the lowest concentration of drug that resulted in no growth (less than 0.1 absorbance unit at 600 nm).
this work may have impact primarily at the point of septal murein synthesis, while elongation remained relatively unaffected.

In *B. subtilis*, depletion of YacN resulted in globular, multicompartimentalized cells with inconsistent wall thickness and regions lacking nucleoid bodies. The rod-to-sphere transition observed in this work is typical of the general response in *B. subtilis* to inhibition of peptidoglycan biosynthesis. Especially striking, however, is the phenotypic similarity to a conditional mutant in teichoic acid biosynthesis, *tagD*, which has been reported on recently (3). TagD encodes glycerol 3-phosphate cytidylyltransferase, which is required for biosynthesis of cell wall teichoic acid. Both TagD- and YacN-depleted strains showed multicompartimentalization and aberrant septum formation along with wall thickening, implying that these features of the phenotype seen with YacN depletion may be a result of a teichoic acid deficiency. Wall teichoic acids are polymers of substituted glycerol or ribitol linked by phosphodiester bridges that are covalently attached to peptidoglycan (1). The biosynthesis of wall teichoic acids requires dolichol phosphate carrier that is substituted glycerol or ribitol linked by phosphodiester bridges and so it is reasonable to speculate that teichoic acid biosynthesis may be affected by depletion of MEC synthase. Additionally, because gram-negative bacteria do not possess teichoic acids, such an effect would not be seen in *E. coli*, consistent with distinct morphologies observed for the two organisms here.

To further probe the predominant mechanism by which MEC synthase depletion is growth inhibitory, we exploited the principle of synthetic lethal interaction. Synthetic lethal screens allow for the identification of interactions between unlinked genes and facilitate the determination of functional relationships (38, 41). Both *ispF* and yacN were placed under tight control of inducible promoters, and the expression of each gene was varied in the presence of a variety of antibiotic agents with diverse mechanisms of action. As inducer levels were decreased, both strains showed an increased sensitivity to cell wall inhibitors and to fosmidomycin. Fosmidomycin was a valuable control in this study, because it inhibits MEP synthase, the first enzyme of the DOXP pathway (20, 21), and sensitization to this antibiotic is consistent with the principle of synthetic lethality. That cell wall inhibitors were also synergistic with MEC synthase depletion suggests that the dominant impact of a lesion in this step was in cell wall biosynthesis in both *E. coli* and *B. subtilis*.

From this work, it is clear that depletion of MEC synthase in both *E. coli* and *B. subtilis* has an early and significant impact on cell wall biosynthesis and leads ultimately to cell death. Cell wall biosynthesis has been and continues to be one of the foremost targets for antibacterial therapeutics, in part, due to the catastrophic outcomes of complete loss of cell shape and lysis that accompany its inhibition. That the DOXP pathway appears to have a particular impact on cell wall biosynthesis in both *E. coli* and *B. subtilis* augurs well for the therapeutic potential of this recently discovered route to isoprenoid synthesis.

ACKNOWLEDGMENTS

We thank Barry Wanner for pKD46 and for advice and help in creating the *E. coli* deletion strain and Tamara O’Connor for assistance with the light microscopy. We appreciate the assistance of Amit Bhavsar and Andy Ho in creating the clones for the yacN deletion strain.

This research was supported by a postgraduate fellowship to T.L.C. from the Natural Sciences and Engineering Research Council of Canada. E.D.B. holds a Canada Research Chair in Microbial Biochemistry.

REFERENCES

1. Archibald, A. R., L. C. Hancock, and C. R. Harwood. 1993. Cell wall structure, synthesis, and turnover, p. 381–410. In A. L. Sonenschein, J. A. Hoch, and R. Losick (ed.), *Bacillus subtilis* and other gram-positive bacteria: biochemistry, physiology, and molecular genetics. American Society for Microbiology, Washington, D.C.

2. Arigoni, D., S. Sagner, C. Latzel, W. Eisenreich, A. Bacher, and M. H. Zenk. 1997. Terpenoid biosynthesis from 1-deoxy-x-xylulose in higher plants by intramolecular skeletal rearrangement. Proc. Natl. Acad. Sci. USA 94: 10600–10605.

3. Bhavsar, A. P., T. J. Beveridge, and E. D. Brown. 2001. Precise deletion of *tagD* and controlled depletion of its product, glycerol 3-phosphate cytidylyltransferase, leads to irregular morphology and lysis of *Bacillus subtilis* grown at physiological temperature. J. Bacteriol. 183: 6688–6693.

4. Bhavsar, A. P., X. Zhao, and E. D. Brown. 2001. Development and characterization of a xylene-sensitive system for expression of cloned genes in *Bacillus subtilis*: conditional complementation of a teichoic acid mutant. Appl. Environ. Microbiol. 67: 403–410.

5. Black, G. R., J. U. Ericson, C. E. Gustafson, T. G. Hagerwall, Y. H. Jonsson, and P. M. Wikstrom. 1987. Transfer RNA modification. Annu. Rev. Biochem. 56:263–287.

6. Briel, M., H. M. Pooley, and D. Karamata. 1989. Mutants of *Bacillus subtilis* 168 thermosensitive for growth and wall teichoic acid biosynthesis. J. Gen. Microbiol. 135:1325–1334.

7. Campos, N., M. Rodriguez-Concepcion, S. Sauret-Gueto, F. Gallego, L. M. Lois, and A. Boronat. 2001. *Escherichia coli* engineered to synthesize isopentenyl diposphate and dimethylallyl diposphate from mevalonate: a novel system for the genetic analysis of the 2-C-methyl-d-erythritol 4-phosphopentane pathway for isoprenoid biosynthesis. Biochem. J. 352:59–67.

8. Cunningham, F. X., Jr., T. P. Lafond, and E. Gantt. 2000. Evidence of a role for LytB in the nonmevalonate pathway of isoprenoid biosynthesis. J. Bacteriol. 182:5841–5848.

9. Cutting, S. M., and P. B. Y. Horn. 1990. Genetic analysis, p. 27–61. In C. R. Harwood and S. M. Cutting (ed.), Molecular biological methods for *Bacillus*. John Wiley and Sons, Toronto, Ontario, Canada.

10. Cutting, S. M., and P. Youngman. 1994. Gene transfer in gram-positive bacteria, p. 348–364. In P. Gerhardt, R. G. E. Murray, W. A. Wood, and N. R. Krieg (ed.), Methods for general and molecular bacteriology. American Society for Microbiology, Washington, DC.

11. Dansen, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K12 using PCR products. Proc. Natl. Acad. Sci. USA 97:6640–6645.

12. Denamur, E., S. A., P. K. EF, T. A. Henderson, D. E. Nelson, and K. D. Young. 1999. *Escherichia coli* mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J. Bacteriol. 181:3981–3993.

13. Dommermuth, M. A., W. D. Donachie, J.-V. Höltje, and H. Schwarz. 2001. Constitutive septal murein synthesis in *Escherichia coli* with impaired activity of the morphogenetic proteins RodA and penicillin-binding protein 2. J. Bacteriol. 183:4115–4126.

14. Eisenreich, W., W. Schwarz, A. Cartayrade, D. Arigoni, M. H. Zenk, and A. Bacher. 1998. The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Chem. Biol. 5:R221–R233.

15. Freiberg, C., B. Wieland, F. Spaltmann, K. Ehler, H. Brotz, and H. Labischinski. 2001. Identification of novel essential *Escherichia coli* genes conserved among pathogenic bacteria. J. Mol. Microbiol. Biotechnol. 3:483–489.

16. Fujisaki, S., T. Nishino, and H. Katsuki. 1986. Biosynthesis of isoprenoids in intact cells of *Escherichia coli*. J. Biochem. 99:1137–1146.

17. Guzman, L.-M., D. Belin, M. J. Carson, and J. Beckwith. 1995. Tight regulation, modulation, and high-level expression by vectors containing the arabino nine *pBAD* promoter. J. Bacteriol. 177:4121–4130.

18. Hecht, S., W. Eisenreich, P. Adam, S. Amslinger, K. Kis, A. Bacher, D. Arigoni, and F. Rohdich. 2001. Studies on the nonmevalonate pathway to terpenes: the role of the GcpE (IspG) protein. Proc. Natl. Acad. Sci. USA 98:14837–14842.

19. Herz, S., J. Wünsingtawekul, C. A. Schuhr, S. Hecht, H. Luttgen, S. Sagner, M. Fellermeier, W. Eisenreich, M. H. Zenk, A. Bacher, and F. Rohdich. 2000. Biosynthesis of terpenoids: YgbB protein converts 4-diphosphocytidyl-2C-methyl-d-erythritol 2-phosphate to 2C-methyl-d-erythritol 2,4-cyclodiphosphate. Proc. Natl. Acad. Sci. USA 97:2486–2490.

20. Jomaa, H., J. Wisnewski, S. M. Zumbried, B. Altmiecke, C. Weidemeyer, M. Hintz, J. Turbachova, M. Eberl, J. Zeidler, H. K. Lichtenhalter, D. Soldati, and E. Beck. 1999. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimarial drugs. Science 285:1573–1576.
